TCI Wealth Advisors’s Cytokinetics CYTK Stock Holding History

TCI Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-144	Closed	-$5.07K	–	703
2023 Q1	$5.07K	Sell	144 -76	-35%	-$3.1K	﹤0.01%	1517
2022 Q4	$10.1K	Buy	220 +77	+54%	+$3.31K	﹤0.01%	1063
2022 Q3	$7K	Hold	143	–	–	﹤0.01%	1235
2022 Q2	$6K	Hold	143	–	–	﹤0.01%	1335
2022 Q1	$5K	Sell	143 -24	-14%	-$853	﹤0.01%	1515
2021 Q4	$8K	Buy	167 +24	+17%	+$926	﹤0.01%	1308
2021 Q3	$5K	Buy	143 +26	+22%	+$765	﹤0.01%	1568
2021 Q2	$2K	Buy	117 +21	+22%	+$493	﹤0.01%	1982
2021 Q1	$2K	Buy	+96	New	+$2.05K	﹤0.01%	1713
2017 Q4	–	Sell	-80	Closed	-$1K	–	1381
2017 Q3	$1K	Hold	80	–	–	﹤0.01%	1088
2017 Q2	$1K	Buy	+80	New	+$1.11K	﹤0.01%	1112

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

TCI Wealth Advisors's CYTK Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 144 shares — an estimated $5.07K sold.

TCI Wealth Advisors first reported a position in CYTK in Q2 2017 and held it in 11 quarters. The position peaked at $10.1K in Q4 2022. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

TCI Wealth Advisors reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 144 Cytokinetics shares in Q2 2023, an estimated $5.07K.
TCI Wealth Advisors first reported a position in Cytokinetics in Q2 2017 and held it in 11 quarters.
TCI Wealth Advisors's Cytokinetics position peaked at $10.1K in Q4 2022.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.